Claude in pharmaceutical drug discovery

Anthropic has embedded Claude across active drug development programs at six partner organizations and launched its own internal drug discovery efforts, reporting early results across several development stages. The six partners are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.

At Divergence Labs, Claude generated roughly 35,000 antibody designs in about a month for a food allergy program, and the candidate molecules outperformed a standard medication. At Enveda, applying Claude to manufacturing documentation review reduced human review time by 89% and identified seven issues human reviewers had missed. One task described in Anthropic's report took four hours compared to about three months by hand. The Column Group used Claude to analyze proprietary data and create a clinical study plan from a single prompt, work that would otherwise take days.

Anthropoi acquired Mithril Medicine, a one-person drug-development company that used Claude to coordinate research across 11 laboratories, with early mouse-study results described as promising. A muscular dystrophy drug candidate from that work could enter human clinical trials as early as late 2028. Anthropic has also begun its own internal drug discovery efforts. Alongside the partnerships, Anthropic launched Claude Science, a Life Sciences Verification Program, and an open call for guest investigators.